Showing results (1891-1900 of 6,794) with videos related to

Sort By:
Pageof 680
Clinical Therapeutics|June 18, 2003
Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient studyGary E Ruoff, Norman Rosenthal, Donna Jordan, et al.
Clinical Therapeutics|June 18, 2003
An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavirMarcelo M Gutierrez, Jeffrey Rosenberg, Wattanaporn Abramowitz
Clinical Therapeutics|June 18, 2003
Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?Nigel S B Rawson
Clinical Therapeutics|June 18, 2003
Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) studyCathryn A Carroll, Michael M Coen, Marilyn M Rymer
Clinical Therapeutics|July 11, 2003
Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetesElizabeth Barrett-Connor, Kristine E Ensrud, Kristine Harper, et al.
Clinical Therapeutics|July 11, 2003
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitisMark B Abelson, Darell Turner
Clinical Therapeutics|July 11, 2003
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumoniaRichard G Wunderink, Sue K Cammarata, Thomas H Oliphant, et al.
Clinical Therapeutics|July 11, 2003
A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapiesMichael Schiff
Clinical Therapeutics|September 1, 1992
(1-Sar, 8-Ile) angiotensin II in the treatment of inhalation injury: a pilot studyT Yukioka, S Shimazaki, H Matuda
Clinical Therapeutics|November 17, 2019
A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational AerosolJohn C Messina, Elliot Offman, Jennifer L Carothers, et al.
Pageof 680